| ◆英語タイトル：Global Conjugate Vaccines Market Size study & Forecast, by Type (Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccines) by Disease Indication (Pneumococcal, Influenza, Diphtheria Tetanus and Pertussis (DTP), Meningococcal, Others), by Pathogen Type (Bacterial Conjugate Vaccine, Viral Conjugate Vaccine, Combination (Viral and Bacterial) Conjugate Vaccine), by End User (Pediatrics, Adults) and Regional Analysis, 2022-2029
|
 | ◆商品コード：BZW23FE0116
◆発行会社（リサーチ会社）：Bizwit Research & Consulting
◆発行日：2023年2月8日
◆ページ数：約200
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後3営業日）
◆調査対象地域：アメリカ、カナダ、イギリス、ドイツ、フランス、スペイン、イタリア、中国、インド、日本、オーストラリア、韓国、ブラジル、メキシコ、中東
◆産業分野：医薬品
|
◆販売価格オプション
（消費税別）
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
Bizwit Research社は、2021年に約XX億ドルであった世界の結合型ワクチン市場規模は、2022年から2029年の間にCAGR XX％増加すると予想しています。本書は、結合型ワクチンの世界市場について調査・分析を行い、エグゼクティブサマリー、市場定義・範囲、市場動向、産業分析、リスク分析（新型コロナウイルス感染症の影響）、種類別（一価結合型ワクチン、多価結合型ワクチン）分析、疾患別（肺炎球菌、インフルエンザ、ジフテリア・破傷風・百日咳（DTP）、髄膜炎菌感染症、その他）分析、病原体種類別（細菌結合型ワクチン、ウィルス結合型ワクチン、混合（ウイルス・細菌）結合型ワクチン）分析、エンドユーザー別（小児科、成人）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、その他地域）分析、競争分析、調査プロセスなどの内容をまとめています。また、本書で記載されている企業情報には、Novartis AG、Neuron Biotech、Serum Institute of India、Pfizer, Inc.、Sanofi Pasteur、Bharat Biotech、Biological E Ltd.、GlaxoSmithKline, plc.、Merck and Companyなどが含まれています。
・エグゼクティブサマリー
・市場定義・範囲
・市場動向
・産業分析
・リスク分析（新型コロナウイルス感染症の影響）
・世界結合型ワクチン市場規模：種類別
- 一価結合型ワクチンの市場規模
- 多価結合型ワクチンの市場規模
・世界結合型ワクチン市場規模：疾患別
- 肺炎球菌における市場規模
- インフルエンザにおける市場規模
- ジフテリア・破傷風・百日咳（DTP）における市場規模
- 髄膜炎菌感染症における市場規模
- その他疾患における市場規模
・世界結合型ワクチン市場規模：病原体種類別
- 細菌結合型ワクチンの市場規模
- ウィルス結合型ワクチンの市場規模
- 混合（ウイルス・細菌）結合型ワクチンの市場規模
・世界結合型ワクチン市場規模：エンドユーザー別
- 小児科における市場規模
- 成人における市場規模
・世界の結合型ワクチン市場規模：地域別
- 北米の結合型ワクチン市場
- ヨーロッパの結合型ワクチン市場
- アジア太平洋の結合型ワクチン市場
- 中南米の結合型ワクチン市場
- その他地域の結合型ワクチン市場
・競争分析
・調査プロセス |
Global Conjugate Vaccines Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. A conjugate vaccine is a kind of subunit vaccine that uses a strong antigen as a carrier to combine a weak antigen with, thus enhancing the immune system’s response to the weak antigen. By enhancing an immune response to an antigen, vaccines are used to avoid diseases like Haemophilus influenzae B (Hib), pneumococcus and others. The key factor driving the market growth of conjugate vaccines is rising government approvals and prevalence of pneumococcal disease globally. Thus, create the lucrative demand for the market during forecast period.
The Conjugate Vaccines is widely used to avoid pneumococcus diseases. Thus, the increasing prevalence of pneumococcus diseases is anticipated to propelling demand for the market during forecast period. According to WHO, 7,40,180 children under the age of five died from pneumonia in 2019, accounting for 14% of all child deaths in that age group but 22% of all pediatric deaths in children from 1 to 5. Children and families worldwide are affected by pneumonia, but South Asia and sub-Saharan Africa have the highest death rates. Also, the rising government approval for Conjugate Vaccines to control the rising prevalence of various types of disease and encouraging market players for introducing a new product. For instance, in April 2020, U.S. Food and Drug Administration (FDA) approved the MenQuadfi Meningococcal Conjugate Vaccine’s Biologics License Application for the treatment of invasive meningococcal disease in people two years of age and older. Also, the constant R&D activities for the development of effective vaccines would create the lucrative opportunity for the market during forecast period. However, the rising side effects associated with the conjugate vaccine stifles market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Conjugate Vaccines Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the dominating region across the world in terms of market share, owing to the occurrence of the refined healthcare expenses and increasing the patient alertness level in the region. Whereas, Asia Pacific is also anticipated to exhibit highest growth rate over the forecast period, owing to factors such as presence of key market players and increasing support from the government for the vaccine development would create lucrative growth prospects for the Conjugate Vaccines market across Asia Pacific region.
Major market player included in this report are:
Novartis AG
Neuron Biotech
Serum Institute of India
Pfizer, Inc.
Sanofi Pasteur
Bharat Biotech
Biological E Ltd.
GlaxoSmithKline, plc.
Merck and Company
CSL Limited
Recent Developments in the Market:
In June 2021, Pfizer Inc. announced that the FDA has approved PREVNAR 20TM (Pneumococcal 20-valent Conjugate Vaccine) for use in people 18 years of age and older to prevent pneumonia and invasive disease brought on by the 20 pneumococcal serotypes contained in the vaccine.
In July 2021, Kenilworth, also known as MSD outside of the USA and Canada, announced that the U.S. Food and Drug Administration (FDA) had approved VAXNEUVANCETM (Pneumococcal 15-valent Conjugate Vaccine) (pronounced VAKS-noo-vans) for use in adults 18 years of age and older as an immunization for the prevention of invasive disease caused by streptococcus pneumoniae.
Global Conjugate Vaccines Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Type, Disease Indication, Pathogen Type, End User, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
Monovalent Conjugate Vaccines
Multivalent Conjugate Vaccines
By Disease Indication:
Pneumococcal
Influenza
Diphtheria Tetanus and Pertussis (DTP)
Meningococcal
Others
By Pathogen Type:
Bacterial Conjugate Vaccine
Viral Conjugate Vaccine
Combination (Viral and Bacterial) Conjugate Vaccine
By End User:
Pediatrics
Adults
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Conjugate Vaccines Market, by Region, 2019-2029 (USD Billion)
1.2.2. Conjugate Vaccines Market, by Type, 2019-2029 (USD Billion)
1.2.3. Conjugate Vaccines Market, by Disease Indication, 2019-2029 (USD Billion)
1.2.4. Conjugate Vaccines Market, by Pathogen Type, 2019-2029 (USD Billion)
1.2.5. Conjugate Vaccines Market, by End User, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Conjugate Vaccines Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Conjugate Vaccines Market Dynamics
3.1. Conjugate Vaccines Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Rising Government Approvals for Conjugate Vaccines
3.1.1.2. Rising Prevalence of Pneumococcal Disease
3.1.2. Market Challenges
3.1.2.1. Rising side effects associated with the conjugate vaccine
3.1.3. Market Opportunities
3.1.3.1. Constant R&D activities for the development of effective vaccines
Chapter 4. Global Conjugate Vaccines Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Investment Adoption Model
4.5. Analyst Recommendation & Conclusion
4.6. Top investment opportunity
4.7. Top winning strategies
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Conjugate Vaccines Market, by Type
6.1. Market Snapshot
6.2. Global Conjugate Vaccines Market by Type, Performance – Potential Analysis
6.3. Global Conjugate Vaccines Market Estimates & Forecasts by Type 2019-2029 (USD Billion)
6.4. Conjugate Vaccines Market, Sub Segment Analysis
6.4.1. Monovalent Conjugate Vaccines
6.4.2. Multivalent Conjugate Vaccines
Chapter 7. Global Conjugate Vaccines Market, by Disease Indication
7.1. Market Snapshot
7.2. Global Conjugate Vaccines Market by Disease Indication, Performance – Potential Analysis
7.3. Global Conjugate Vaccines Market Estimates & Forecasts by Disease Indication 2019-2029 (USD Billion)
7.4. Conjugate Vaccines Market, Sub Segment Analysis
7.4.1. Pneumococcal
7.4.2. Influenza
7.4.3. Diphtheria Tetanus and Pertussis (DTP)
7.4.4. Meningococcal
7.4.5. Others
Chapter 8. Global Conjugate Vaccines Market, by Pathogen Type
8.1. Market Snapshot
8.2. Global Conjugate Vaccines Market by Pathogen Type, Performance – Potential Analysis
8.3. Global Conjugate Vaccines Market Estimates & Forecasts by Pathogen Type 2019-2029 (USD Billion)
8.4. Conjugate Vaccines Market, Sub Segment Analysis
8.4.1. Bacterial Conjugate Vaccine
8.4.2. Viral Conjugate Vaccine
8.4.3. Combination (Viral and Bacterial) Conjugate Vaccine
Chapter 9. Global Conjugate Vaccines Market, by End User
9.1. Market Snapshot
9.2. Global Conjugate Vaccines Market by End User, Performance – Potential Analysis
9.3. Global Conjugate Vaccines Market Estimates & Forecasts by End User 2019-2029 (USD Billion)
9.4. Conjugate Vaccines Market, Sub Segment Analysis
9.4.1. Pediatrics
9.4.2. Adults
Chapter 10. Global Conjugate Vaccines Market, Regional Analysis
10.1. Conjugate Vaccines Market, Regional Market Snapshot
10.2. North America Conjugate Vaccines Market
10.2.1. U.S. Conjugate Vaccines Market
10.2.1.1. Type breakdown estimates & forecasts, 2019-2029
10.2.1.2. Disease Indication breakdown estimates & forecasts, 2019-2029
10.2.1.3. Pathogen Type breakdown estimates & forecasts, 2019-2029
10.2.1.4. End User breakdown estimates & forecasts, 2019-2029
10.2.2. Canada Conjugate Vaccines Market
10.3. Europe Conjugate Vaccines Market Snapshot
10.3.1. U.K. Conjugate Vaccines Market
10.3.2. Germany Conjugate Vaccines Market
10.3.3. France Conjugate Vaccines Market
10.3.4. Spain Conjugate Vaccines Market
10.3.5. Italy Conjugate Vaccines Market
10.3.6. Rest of Europe Conjugate Vaccines Market
10.4. Asia-Pacific Conjugate Vaccines Market Snapshot
10.4.1. China Conjugate Vaccines Market
10.4.2. India Conjugate Vaccines Market
10.4.3. Japan Conjugate Vaccines Market
10.4.4. Australia Conjugate Vaccines Market
10.4.5. South Korea Conjugate Vaccines Market
10.4.6. Rest of Asia Pacific Conjugate Vaccines Market
10.5. Latin America Conjugate Vaccines Market Snapshot
10.5.1. Brazil Conjugate Vaccines Market
10.5.2. Mexico Conjugate Vaccines Market
10.6. Rest of The World Conjugate Vaccines Market
Chapter 11. Competitive Intelligence
11.1. Top Market Strategies
11.2. Company Profiles
11.2.1. Novartis AG
11.2.1.1. Key Information
11.2.1.2. Overview
11.2.1.3. Financial (Subject to Data Availability)
11.2.1.4. Product Summary
11.2.1.5. Recent Developments
11.2.2. Neuron Biotech
11.2.3. Serum Institute of India
11.2.4. Pfizer, Inc.
11.2.5. Sanofi Pasteur
11.2.6. Bharat Biotech
11.2.7. Biological E Ltd.
11.2.8. GlaxoSmithKline, plc.
11.2.9. Merck and Company
11.2.10. CSL Limited
Chapter 12. Research Process
12.1. Research Process
12.1.1. Data Mining
12.1.2. Analysis
12.1.3. Market Estimation
12.1.4. Validation
12.1.5. Publishing
12.2. Research Attributes
12.3. Research Assumption
❖ 免責事項 ❖http://www.globalresearch.jp/disclaimer